Compare FUND & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUND | ELDN |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.2M | 291.8M |
| IPO Year | N/A | 2014 |
| Metric | FUND | ELDN |
|---|---|---|
| Price | $10.61 | $2.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 25.1K | ★ 947.9K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.97 | $1.35 |
| 52 Week High | $10.99 | $4.60 |
| Indicator | FUND | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 54.20 | 31.65 |
| Support Level | $9.87 | $2.68 |
| Resistance Level | $10.96 | $3.21 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 15.93 | 10.88 |
Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, the Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.